Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Radiation Therapy Oncology Group
National Cancer Institute (NCI)
AstraZeneca
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Tesaro, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Wake Forest University Health Sciences
Merck Sharp & Dohme LLC
Tesaro, Inc.
Universitaire Ziekenhuizen KU Leuven
M.D. Anderson Cancer Center
NRG Oncology
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
Aprea Therapeutics
EpicentRx, Inc.
Washington University School of Medicine
Deciphera Pharmaceuticals, LLC
Opna Bio LLC
AbbVie
Hoffmann-La Roche
Astex Pharmaceuticals, Inc.
AstraZeneca
University of Miami
ImmunoGen, Inc.
University of Oklahoma
EMD Serono
Albert Einstein College of Medicine
Medical College of Wisconsin
University of Miami
Albert Einstein College of Medicine
AstraZeneca
Merck Sharp & Dohme LLC
Albert Einstein College of Medicine
Canadian Cancer Trials Group
Albert Einstein College of Medicine
City of Hope Medical Center
Eisai Inc.
pharmaand GmbH
Hoffmann-La Roche